logo-loader
Faron Pharmaceuticals Ltd

Faron Pharmaceuticals makes good progress with Clevegen immunotherapy trial

Snapshot

  • First-in-person trial underway for Clevegen cancer treatment
  • Patients dosed showed a rise in natural killer cells and T-Cells
  • Patient’s tumour shrank after treatment
  • Clevegen may be able to reactivate T-Cells in cancer sufferers
cancer

Quick facts: Faron Pharmaceuticals Ltd

Price: 130 GBX

Market: AIM
Market Cap: £51.16 m
Follow

 

How is it doing

Immunotherapy treatment Clevegen is on phase I/II trial (MATINS) for metastatic cutaneous melanoma as well as hepatobiliary/hepatocellular, pancreatic, ovarian and colorectal cancers.

Tumour cells are adept at creating a shield around themselves to evade detection by the immune system, therefore staving off destruction.

Clevegen has been designed to recognise cancer and break the cell’s protective shell.

The treatment is an anti-Clever-1 antibody which causes changes in the immune environment of solid tumours by switching Clever-1 positive immune suppressive macrophages to immune active macrophages.

Ultimately, if it is successful, this new breed of treatment will be used in combination with PD-1 inhibitors to tackle the killer disease.

Traumakine

Clevegen has helped the company rebuild after a major disappointment with another drug Traumakine.

A phase III trial as a treatment for lung inflammation condition ARDS missed its target and there was no benefit against the placebo.

Faron (LON:FARN) is working with drug regulators to work out why the results were poor and is confident Traumakine can be of benefit to some patients.

 

What the boss says: Markku Jalkanen, CEO

“We are thrilled with the progress the MATINS [Clevegen] study has made during the last few months.
“We believe we have the first macrophage immune checkpoint drug in clinical development promoting immune activation and are encouraged by the latest data indicating potential early efficacy and good tolerability.
“We expect to progress the cohort expansion phase of the study in Q3 2019 in patients with late-stage colorectal cancer.”

 

Video

Inflection points

• In October, Faron said its Clevegen treatment could potentially induce a "stronger immune response" at lower doses, increasing its safety margins
• Faron finds a partner from the many said to be watching MATINS trial data
• Shares doubled since results from MATINS trial started to be released
• Traumakine reboots as a treatment for a specific type of ARDS sufferer who has a special type of genetic mutation known as C/T.

 

Blue Sky

If Clevegen proves to a way of re-awakening T-cells in metastatic tumours, the potential as an immunotherapy treatment is enormous
Traumakine is a smaller opportunity now but still substantial for Faron
Before the Traumakine trial result, the shares almost reached 900p.

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

'Immune activation from Clevegen has now been demonstrated' Faron Pharma CEO

Faron Pharmaceuticals Oy's (LON:FARN) Markku Jalkanen caught up with Proactive London's Andrew Scott to discuss the recently released Matins trial update which is assessing the firm's drug Clevegen. He says feedback from the dose escalation study confirmed Clevegen has good tolerability...

3 days, 15 hours ago

RNS

Second Price Monitoring Extn

1 week, 2 days ago

Price Monitoring Extension

1 week, 2 days ago

Matins Trial Update

1 week, 4 days ago

Notice of EGM

2 weeks, 2 days ago

Holdings in Company

3 weeks, 4 days ago

Interim results

3 weeks, 6 days ago

2 min read